CANTON, Mass., Oct. 26 /PRNewswire-FirstCall/ -- Avitar, Inc. (Amex: - ) today announced that Richard Anderson, vice president of research and development for Avitar, and a co-founder of BioSite, will speak at the upcoming Rosita-2 Forum, November 12 - 13 in Santiago de Compostela, Spain. Rosita-2 is a multi-year project for the evaluation of roadside oral fluid drug tests and other appropriate on-site tests, carried out in six countries in Europe and several major U.S. cities.
The EU Project Rosita (Roadside Testing Assessment) was conceived in 1999 to address the growing problems in the European Union associated with driving under the influence (DUI). The Project provides comparative assessments of DUI trends and management capabilities, including identifying requirements for roadside drug and alcohol testing devices. In a report titled, "Drugs and Medicines That Are Suspected to Have a Detrimental Impact on Road User Performance," as many as 85% of drivers injured or killed in accidents were suspected of drug abuse.
Technology has advanced rapidly since the initial study and Rosita-2 aims to assess current equipment in terms of the reliability and usability of roadside drug testing.
Among others, Avitar's ORALscreen(TM), rapid, oral-based tests for drugs- of-abuse will be used by coordinators and administrators of the Rosita-2 project. As part of the project, drivers will be stopped randomly and subjected to drug tests at roadside. The results will be evaluated by drug recognition experts and officials to determine the cost-effectiveness and usability of oral fluid diagnostics for roadside drug tests.
"Being asked to participate in the study validates Avitar's position as a technology leader," said Anderson. "Avitar created the market for disposable, cost-effective, oral drug screens by introducing the world's first product of its kind and we are looking forward to supporting this important program."
Avitar, Inc. develops, manufactures and markets innovative and proprietary products in the oral fluid diagnostic market and customized medical grade polyurethane foam. Oral fluid diagnostics includes the estimated $1.5 billion drugs-of-abuse testing market, which encompasses the corporate workplace, school, and criminal justice markets. Avitar's products include ORALscreen® the world's first non-invasive, rapid, onsite oral fluid test for drugs-of- abuse. Additionally, Avitar manufactures and markets HYDRASORB® an absorbent topical dressing for wound care. For more information, see Avitar's website at https://avitarinc.com.
Safe Harbor Statement. This release contains forward looking statements that are subject to risks and uncertainties including the development and marketing of new applications and other risks that are detailed from time to time in the Company's filings with the Securities and Exchange Commission. In view of such risks and uncertainties, the Company's actual results could differ materially from those anticipated in such forward looking statements.
|Peter N. Cholakis
VP of Marketing
Avitar, Technologies, Inc.